Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries

American Heart Journal

Volumn 179, Issue , 2016, Pages 10-18

  Jones, W Schuyler ^a   Mi, Xiaojuan ^a   Qualls, Laura G ^a   Turley, Ryan S ^a   Vemulapalli, Sreekanth ^a   Peterson, Eric D ^a   Patel, Manesh R ^a   Curtis, Lesley H ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR INHIBITOR; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

AGED; ARTICLE; BLACK PERSON; DEMENTIA; HEART FAILURE; HUMAN; KIDNEY DISEASE; LOWER LIMB; MAJOR CLINICAL STUDY; MALE; MEDICARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICIAN; PRIORITY JOURNAL; VERY ELDERLY; AFRICAN AMERICAN; AGE; ANGIOPLASTY; ATHERECTOMY; CARDIOLOGIST; FEMALE; INTERVENTIONAL RADIOLOGY; KIDNEY DISEASES; PERIPHERAL VASCULAR DISEASES; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; RADIOLOGIST; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; STENT; SURGEON; UNITED STATES; VASCULAR SURGERY;

AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOPLASTY; ATHERECTOMY; CARDIOLOGISTS; DEMENTIA; FEMALE; GUIDELINE ADHERENCE; HEART FAILURE; HUMANS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MEDICARE; PERIPHERAL VASCULAR DISEASES; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RADIOLOGISTS; RADIOLOGY, INTERVENTIONAL; SEX FACTORS; STENTS; SURGEONS; UNITED STATES; VASCULAR SURGICAL PROCEDURES;

EID: 84976644525     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.06.002     Document Type: Article

References (38)

1. [1] Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006), e463–e654.
2. [2] 2011 Writing Group Members, 2005 Writing Committee Members, ACCF/AHA Task Force Members, 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 124 (2011), 2020–2045.
3. [3] Jaff, M.R., Cahill, K.E., Yu, A.P., et al. Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease. Ann Vasc Surg 24 (2010), 577–587.
4. [4] Alberts, M.J., Bhatt, D.L., Mas, J.L., et al. Three-year follow-up and event rates in the international reduction of atherothrombosis for continued health registry. Eur Heart J 30 (2009), 2318–2326.
5. [5] European Stroke Organisation, Tendera, M., Aboyans, V., et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 32 (2011), 2851–2906.
6. [6] Guyatt, G.H., Akl, E.A., Crowther, M., et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), 7S–47S.
7. [7] Feringa, H.H., van Waning, V.H., Bax, J.J., et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 47 (2006), 1182–1187.
8. [8] Robertson, L., Ghouri, M.A., Kovacs, F., Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev, 8, 2012, CD002071.
9. [9] Schmit, K., Dolor, R.J., Jones, W.S., et al. Comparative effectiveness review of antiplatelet agents in peripheral artery disease. J Am Heart Assoc, 3, 2014, e001330.
10. [10] Subherwal, S., Patel, M.R., Kober, L., et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 126 (2012), 1345–1354.
11. [11] Hoeks, S.E., Scholte op Reimer, W.J., van Gestel, Y.R., et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes 2 (2009), 338–343.
12. [12] Pande, R.L., Perlstein, T.S., Beckman, J.A., et al. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 124 (2011), 17–23.
13. [13] Ardati, A.K., Kaufman, S.R., Aronow, H.D., et al. The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. Circ Cardiovasc Interv 5 (2012), 850–855.
14. [14] Armstrong, E.J., Chen, D.C., Westin, G.G., et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc, 3, 2014, e000697.
15. [15] Goodney, P.P., Beck, A.W., Nagle, J., et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg 50 (2009), 54–60.
16. [16] Jones, W.S., Mi, X., Qualls, L.G., et al. Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system. J Am Coll Cardiol 65 (2015), 920–927.
17. [17] Nowygrod, R., Egorova, N., Greco, G., et al. Trends, complications, and mortality in peripheral vascular surgery. J Vasc Surg 43 (2006), 205–216.
18. [18] Scheinert, D., Duda, S., Zeller, T., et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 7 (2014), 10–19.
19. [19] Tepe, G., Laird, J., Schneider, P., et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 131 (2015), 495–502.
20. [20] Zeller, T., Dake, M.D., Tepe, G., et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv 6 (2013), 274–281.
21. [21] Adam, D.J., Beard, J.D., Cleveland, T., et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 366 (2005), 1925–1934.
22. [22] Dake, M.D., Ansel, G.M., Jaff, M.R., et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 4 (2011), 495–504.
23. [23] Duda, S.H., Bosiers, M., Lammer, J., et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 13 (2006), 701–710.
24. [24] Laird, J.R., Katzen, B.T., Scheinert, D., et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 3 (2010), 267–276.
25. [25] Mwipatayi, B.P., Thomas, S., Wong, J., et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg 54 (2011), 1561–1570.
26. [26] Zeller, T., Rastan, A., Sixt, S., et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol 48 (2006), 1573–1578.
27. [27] Allemang, M.T., Rajani, R.R., Nelson, P.R., et al. Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures. Ann Vasc Surg 27 (2013), 62–67.
28. [28] Milani, R.V., Antiplatelet therapy after endovascular intervention: Does combination therapy really work and what is the optimum duration of therapy?. Catheter Cardiovasc Interv 74:Suppl. 1 (2009), S7–S11.
29. [29] Mehta, S.R., Yusuf, S., Peters, R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
30. [30] Steinhubl, S.R., Berger, P.B., Mann, J.T. III, et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002), 2411–2420.
31. [31] Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
32. [32] Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
33. [33] Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
34. [34] Morrow, D.A., Braunwald, E., Bonaca, M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366 (2012), 1404–1413.
35. [35] Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
36. [36] Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
37. [37] Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
38. [38] Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.